| 000 | 01791 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514053755.0 | ||
| 264 | 0 | _c20030723 | |
| 008 | 200307s 0 0 eng d | ||
| 022 | _a0305-7453 | ||
| 024 | 7 |
_a10.1093/jac/dkg045 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBongiovanni, Marco | |
| 245 | 0 | 0 |
_aImmunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study. _h[electronic resource] |
| 260 |
_bThe Journal of antimicrobial chemotherapy _cJan 2003 |
||
| 300 |
_a171-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLopinavir |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 |
_aPyrimidinones _xadverse effects |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRitonavir _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBini, Teresa | |
| 700 | 1 | _aTordato, Federica | |
| 700 | 1 | _aCicconi, Paola | |
| 700 | 1 | _aMelzi, Sara | |
| 700 | 1 | _aRepetto, Dolores | |
| 700 | 1 | _aSollima, Salvatore | |
| 700 | 1 | _aRusconi, Stefano | |
| 700 | 1 | _ad'Arminio Monforte, Antonella | |
| 773 | 0 |
_tThe Journal of antimicrobial chemotherapy _gvol. 51 _gno. 1 _gp. 171-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/jac/dkg045 _zAvailable from publisher's website |
| 999 |
_c12297814 _d12297814 |
||